Effective treatment of hypertension by AT1 receptor antagonism: The past and future of telmisartan

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 5, 2006, Pages 615-629

  Goebel, Matthias ^a   Clemenz, Markus ^a   Unger, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiotensin II receptor blocker; Diabetes; Hypertension; Metabolic syndrome; Renin angiotensin system; Telmisartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATACAND HCT; ATACAND PLUS; ATACAND PROTECT; ATENOLOL; AVALIDE; BENICAR PLUS; BISOPROLOL; BLOPRESS PLUS; CANDESARTAN HEXETIL; CHLORTALIDONE; CYTOCHROME P450; EPROSARTAN; FORTZAAR; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IBUPROFEN; INDAPAMIDE; IRBESARTAN; KINZALKOMB; KINZALMONO; LACIDIPINE; LORZAAR PROTECT; LOSARTAN POTASSIUM; METOLAZONE; MICARDIS HCT; NICARDIPINE; NIFEDIPINE; OLMESARTAN; OLMETEC PLUS; PARACETAMOL; PLACEBO; SIMVASTATIN; TELMISARTAN; TEVETEN HCT; TEVETEN MONO; TEVETEN PLUS; UNINDEXED DRUG; VALSARTAN; VOTUM PLUS;

ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FATIGUE; FETUS DEATH; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PHARMACODYNAMICS; PROTEIN BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; DIURETICS; DRUG THERAPY, COMBINATION; DRUG TOXICITY; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; TREATMENT OUTCOME;

EID: 33750982155     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.5.615     Document Type: Article

References (116)

1. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J. Hypertens. 17(2), 151-183 (1999).
2. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood. Pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
3. 3 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21(6), 1011-1053 (2003).
4. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am. J. Cardiol. 89(2A), 3A-9A (2002).
5. de Gasparo M, Catt KJ, Inagami T et al. International Union of Pharmacology. XXIII. The Angiotensin II Receptors. Pharmacol. Rev. 52(3), 415-472 (2000).
6. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 12(2), 70-88 (2003).
7. Dina R, Jafari M. Angiotensin II-receptor antagonists: an overview. Am. J. Health Syst. Pharm. 57(13), 1231-1241 (2000).
8. Unger T. Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications. J. Renin Angiotensin Aldosterone Syst. 2 (Suppl. 2), S4-S7 (2001).
9. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J. Hum. Hypertens. 14(Suppl. 1), S73-S86 (2000).
10. Trenkwalder P. AT1-receptor blocker-based combination therapy in hypertension. Blood Press. Suppl. (3), 18-25 (2001).
11. Kirch W, Horn B, Schweizer J. Comparison of angiotensin II receptor antagonists. Eur. J. Clin. Invest. 31(8), 698-706 (2001).
12. de Gasparo M. AT1 receptor antagonists: pharmacology. In: Part 5. Inhibition of the Renin-Angiotensin System. Angiotensin - Vol. II. Series: Handbook of Experimental Pharmacology (Vol. 163). Unger T Schölkens BA (Eds). Springer Verlag, Heidelberg, Germany 417-452 (2004).
13. Unger T, Chung O, Csikos T et al. Angiotensin receptors. J. Hypertens. 14(Suppl. 5), S95-S103 (1996).
14. Maillard MP, Perregaux C, Centeno C et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 302(3), 1089-1095 (2002).
15. Wienen W, Hauel N, Van Meel JC et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br. J. Pharmacol. 110(1), 245-252 (1993).
16. Schupp M, Janke J, Clasen R et al. Angiotensin Type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109(17), 2054-2057 (2004).
17. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARg-modulating activity. Hypertension 43(5), 993-1002 (2004).
18. Lazar MA. PPARγ, 10 years later. Biochimie 87(1), 9-13 (2005).
19. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26(5), 244-251 (2005).
20. Picard F, Auwerx J. PPAR(γ) and glucose homeostasis. Ann. Rev. Nutr. 22, 167-197 (2002).
21. Campbell IW. The clinical significance of PPAR γ agonism. Curr. Mol. Med. 5(3), 349-363 (2005).
22. Pittas AG, Greenberg AS. Thiazolidinediones in the treatment of Type 2 diabetes. Expert Opin. Pharmacother. 3(5), 529-540 (2002).
23. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54(8), 2460-2470 (2005).
24. Schupp M, Clemenz M, Gineste R et al. Molecular characterization of new selective peroxisome proliferator-activated receptor {γ} modulators with angiotensin receptor blocking activity. Diabetes 54(12), 3442-3452 (2005).
25. Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-γ activator. Acta Diabetol. 42(Suppl 1), S9-S16 (2005).
26. Clasen R, Schupp M, Foryst-Ludwig A et al. PPARγ-activating angiotensin Type-1 receptor blockers induce adiponectin. Hypertension 46(1), 137-143 (2005).
27. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obesity Reviews 6(1), 13-21 (2005).
28. Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPAR[γ]-agonist-mediated improvements in hepatic insulin sensitivity? Int. J. Obes. (Lond) 29(S1), S17-S23 (2005).
29. Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and cardiovascular disease. Biochimie 86(11), 779-784 (2004).
30. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 355(9204), 637-645 (2000).
31. Smith DH, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J. Clin. Pharmacol. 40(12 Pt 1), 1380-1390 (2000).
32. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 61(10), 1501-1529 (2001).
33. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am. J. Hypertens. 17(4), 347-353 (2004).
34. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J. Clin. Hypertens. (Greenwich) 5(1), 58-63 (2003).
35. Neutel JM, Klein C, Meinicke TW et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press. 11(5), 302-309 (2002).
36. Frytag F, Holwerda NJ, Karlberg BE et al. Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. Blood Press. 11(3), 173-181 (2002).
37. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J. Int. Med. Res. 28(4), 149-167 (2000).
38. Karlberg BE, Lins LE, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J. Hypertens. 17(2), 293-302 (1999).
39. Stangier J, Su CA, van Heiningen PN et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J. Cardiovasc. Pharmacol. 38(5), 672-685 (2001).
40. White WB, Giles T, Bakris GL et al. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am. Heart J. 151(1), 176-184 (2006).
41. White WB, Weber MA, Davidai G et al. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press. Monit. 10(3), 157-163 (2005).
42. Derosa G, Ragonesi PD, Mugellini A et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, Type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens. Res. 27(7), 457-464 (2004).
43. Lacourciere Y, Krzesinski JM, White WB et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press. Monit. 9(4), 203-210 (2004).
44. Smith DH, Cramer MJ, Neutel JM et al. Comparison of tetmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press. Monit. 8(3), 111-117 (2003).
45. Stergiou GS, Efstathiou SP, Roussias LG et al. Blood pressure- and pulse pressure-lowering effects, trough: peak ratio and smoothness index of telmisartan compared with lisinopril. J. Cardiovasc. Pharmacol. 42(4), 491-496 (2003).
46. Smith DH. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin. Ther. 24(10), 1484-1501 (2002).
47. Lacourciere Y, Neutel JM, Davidai G et al. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am. J. Hypertens. 19(1), 104-112 (2006).
48. Ragot S, Ezzaher A, Meunier A et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J. Hum. Hypertens. 16(12), 865-873 (2002).
49. Williams B, Gosse P, Lowe L et al. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J. Hypertens. 24(1), 193-200 (2006).
50. Smith D, Morgenstern P, Neutel J. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv. Ther. 15(4), 229-240 (1998).
51. Lacourciere Y, Lenis J, Orchard R et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press. Monit. 3(5), 295-302 (1998).
52. Derosa G, Cicero AF, Bertone G et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with Type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin. Ther. 26(8), 1228-1236 (2004).
53. Freytag F, Schelling A, Meinicke T et al. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin. Ther. 23(1), 108-123 (2001).
54. Galzerano D, Tammaro P, Cerciello A et al. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J. Hum. Hypertens. 18(1), 53-59 (2004).
55. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin. Ther. 23(6), 833-850 (2001).
56. Vitale C, Mercuro G, Castiglioni C et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc. Diabetol. 4, 6 (2005).
57. Sharma A, Davidson J, Gavin III J et al. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and Type 2 diabetes. Hypertension 46(4), 898-899 (2005).
58. Barnett AH, Bain SC, Bouter P et al. Angiotensin-reccptor blockade versus converting-enzyme inhibition in Type 2 diabetes and nephropathy. N. Engl. J. Med. 351(19), 1952-1961 (2004).
59. Maillard M, Burnier M. Telmisartan/hydrochlorothiazide: a new fixed dose combination. Expert Rev. Cardiovasc. Ther. 3(3), 375-386 (2005).
60. Lacourciere Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/ hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: Pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin. Ther. 27(11), 1795-1805 (2005).
61. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr. Hypertens. Rep. 4(5), 343-349 (2002).
62. Moser M, Black HR. The role of combination therapy in the treatment of hypertension. Am. J. Hypertens. 11(6 Pt 2), 73S-78S (1998).
63. Schmieder RE. Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension. Expert Opin. Pharmacother. 5(11), 2303-2310 (2004).
64. Law MR, Wald NJ, Morris JK et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326(7404), 1427 (2003).
65. Ingino C, Farsang C, Laucevicius A et al. An open-label study investigating the efficacy and safety of 12-96 weeks of telmisartan treatment in patients with hypertension. J. Int. Med. Res. 31(6), 561-574 (2003).
66. Michel MC, Bohner H, Koster J et al. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf. 27(5), 335-344 (2004).
67. Young CL, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J. Clin. Pharmacol. 40(12 Pt 1), 1323-1330 (2000).
68. McGill JB, Reilly PA. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin. Cardiol. 24(1), 66-72 (2001).
69. Bakris GL, Smith DH, Giles TD et al. Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients. J. Clin. Hypertens. (Greenwich) 7(10), 587-95 (2005).
70. Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am. J. Cardiol. 91(10, Suppl. 1), 28-34 (2003).
71. Clemenz M, Kintscher U, Unger T. The metabolic syndrome: cluster with a self-fulfilling loop? J. Hypertens. 24(2), 257-258 (2006).
72. Scheen AJ. Renin-angiotensin system inhibition prevents Type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 30(6), 487-496 (2004).
73. Abuissa H, Jones PG, Marso SP et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of Type 2 diabetes: a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol 46(5), 821-826 (2005).
74. Gillespie EL, White CM, Kardas M et al. The impact of ACE inhibitors or angiotensin II Type 1 receptor blockers on the development of new-onset Type 2 diabetes. Diabetes Care 28(9), 2261-2266 (2005).
75. Miura Y, Yamamoto N, Tsunekawa S et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with Type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 28(3), 757-758 (2005).
76. Honjo S, Nichi Y, Wada Y et al. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 28(2), 498 (2005).
77. Asmar R, Gosse P, Topouchian J et al. Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. J. Renin Angiotensin Aldosterone Syst. 3(3), 176-180 (2002).
78. Aranda P. Segura J, Ruilope LM et al. Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am. J. Kidney Dis. 46(6), 1074-1079 (2005).
79. Vogt L, Navis G, Koster J et al. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J. Hypertens. 23(11), 2055-2061 (2005).
80. Rysava R, Tesar V. Merta M. Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease. Blood Press. Monit. 10(4), 207-213 (2005).
81. Sharma AM, Hollander A, Koster J. Telmisartan in patients with mild/ moderate hypertension and chronic kidney disease. Clin. Nephrol. 63(4), 250-257 (2005).
82. Kulkarni RB, Kulkarni BN, Hariharan RS et al. A pilot study for evaluation of the efficacy and safety of telmisartan in reducing microalbuminuria in hypertensive patients with Type 2 diabetes mellitus. J. Indian Med. Assoc. 103(3), 187-191 (2005).
83. Mattioli AV, Zennaro M, Bonatti S et al. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int. J. Cardiol. 97(3), 383-388 (2004).
84. Ivanova OV, Fomicheva OA, Sergakova LM et al. Angiotensin II receptor blocker telmisartan: effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension. J. Int. Med. Res. 33 (Suppl. 1), 21A-29A (2005).
85. Mattioli AV, Bonatti S, Monopoli D et al. Influence of regression of left ventricular hypertrophy on left atrial size and function in patients with moderate hypertension. Blood Press. 14(5), 273-278 (2005).
86. Conrady AO, Kiselev IO, Usachev NI et al. Effect of 24-week treatment with telmisartan on myocardial structure and function: relationship to insertion/deletion polymorphism of the angiotensin-converting enzyme gene. J. Int. Med. Res. 33(Suppl. 1), 30A-38A (2005).
87. Martina B, Dieterle T, Sigle JP et al. Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial. Cardiology 99(3), 169-170 (2003).
88. Fountoulaki K, Dimopoulos V, Giannakoulis J et al. Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartan. Am. J. Hypertens. 18(2 Pt 1), 171-177 (2005).
89. Galzerano D, Tammaro P, del Viscovo L et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am. J. Hypertens. 18(12 Pt 1), 1563-1569 (2005).
90. Petrovic I, Petrovic D, Vukovic N et al. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J. Int. Med. Res. 33(Suppl. 1), 39A-49A (2005).
91. Fogari R, Mugellini A, Zoppi A et al. Effect of telmisartan/ hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J. Hum. Hypertens. 20(3), 177-185 (2006).
92. Nakamura K, Yamagishi S, Nakamura Y et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc. Res. 70(3), 137-141 (2005).
93. Celik T, Iyisoy A, Kursaklioglu H et al. The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study. Clin. Cardiol. 28(6), 298-302 (2005).
94. Karas M, Lacourciere Y, LeBlanc AR et al. Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients. J. Hypertens. 23(6), 1251-1260 (2005).
95. Fogari R, Preti P, Zoppi A et al. Effect of telmisartan/ hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation. Am. J. Hypertens. 18(5 Pt 1), 577-583 (2005).
96. Ghiadoni L, Magagna A, Versari D et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 41(6), 1281-1286 (2003).
97. Saez GT Tormos C, Giner V et al. Factors related to the impact of antihypertensive treatment in antioxidant activities and oxidative stress by-products in human hypertension. Am. J. Hypertens. 17(9), 809-816 (2004).
98. Dunselman PH. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Int. J. Cardiol. 77(2-3), 131-138 (2001).
99. Parker AB, Azevedo ER, Baird MG et al. ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada. Am. Heart J. 138(5 Pt 1), 843-848 (1999).
100. Weber M. The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J. Hypertens. 21 (Suppl. 6), S37-S46 (2003).
101. Neldam S, Edwards C. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am. J. Geriatr. Cardiol. 15(3), 151-160 (2006).
102. Neutel JM, Littlejohn TW, Chrysant SG et al. Telmisartan/ hydrochlorothiazide in comparison with losartan/ hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens. Res. 28(7), 555-563 (2005).
103. Makino H, Haneda M, Babazono T et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy-rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. J. Int. Med. Res. 33(6), 677-686 (2005).
104. Teo K, Yusuf S, Sleight P et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am. Heart J. 148(1), 52-61 (2004).
105. Sleight P. The ONTARGET/TRANSCEND Trial Programme: baseline data. Acta. Diabetol. 42(Suppl. 1), S50-S56 (2005).
106. Anderson C. Rationale and design of the cardiac magnetic resonance imaging sudstudy of The ONTARGET Trial Programme. J. Int. Med. Res. 33(Suppl. 1), 50A-57A (2005).
107. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res. A Clin. Mol. Teratol. 73(2), 123-130 (2005).
108. Moller DE, Kaufman KD. METABOLIC SYNDROME: A Clinical and Molecular Perspective. Ann. Rev. Med. 56(1), 45-62 (2005).
109. Krousel-Wood M, Hyre A, Muntner P et al. Methods to improve medication adherence in patients with hypertension: current status and future directions. Curr. Opin. Cardiol. 20(4), 296-300 (2005).
110. Mancia G, Seravalle G, Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists. Am. J. Hypertens. 16(12), 1066-1073 (2003).
111. McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 56(5), 847-869 (1998).
112. Gleiter CH, Morike KE. Clinical pharmacokinetics of candesartan. Clin. Pharmacokinet. 41(1), 7-17 (2002).
113. Oparil S. Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists. J. Hum. Hypertens. 16(Suppl 2), S17-S23 (2002).
114. Schmieder RE. Endothelial dysfunction: how can one intervene at the beginning of the cardiovascular continuum? J. Hypertens. Suppl. 24(2), S31-S35 (2006).
115. Schmieder RE, Delles C, Mimran A et al. Effects of telmisartan versus ramipril on endothelium function of the renal vasculature in Type 2 diabetes. J. Hypertens. 23(Suppl. 2), 147 (2005).
116. Boger RH, Schwedhelm E, Maas R et al. ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study. Vasc. Med. 10(Suppl. 1), S97-S102 (2005).